An observational study in Human Immunodeficiency Virus (HIV) and Hepatitis c, sponsored by University Hospital, Bordeaux. Completed at 1 site in France. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-14.
Sponsored by University Hospital, Bordeaux · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 174 studies in Hepatitis C with a site in France — 10 open to participants now, 12 under way, 1 of them phase 3. Hepatitis C · France.
Among the 174 studies in Hepatitis C with a site in France, this one is the 41st largest by enrollment of the 45 observational ones that give a count, is one of 14 that started in 2017, is one of 45 observational ones, and was the 145th registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →10 of the 174 studies in Hepatitis C with a site in France are open now. Recruiting first, the newest first:
University Hospital, Rouen · Sites in France
Ages 18+
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Ages 18+
University Hospital, Limoges · Sites in France
Ages 18+ · Healthy volunteers
DatAids · Sites in France, Guadeloupe, Martinique
Ages 18+
Rigshospitalet, Denmark · Sites in France, Argentina, Austria and 33 more countries
Ages 16+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
174 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 50 · Phase 3 56 · Phase 4 3
First in 1994; this study’s year is marked. 14 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 218 across 435 observational studies indexed under Hepatitis C.
Median enrollment 200 across the 129 interventional studies, 300 across the 45 observational. Of the 141 that completed or were terminated, 66 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
102 of 174 have an industry lead sponsor. The 10 most frequent:
University Hospital, Bordeaux is the lead sponsor of 807 studies on the registry; 198 are open to participants now.
University Hospital, Bordeaux has 3 studies filed under Hepatitis C — fewer than ten, so there is no comparison to draw.
3 of the studies in Hepatitis C with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07037277Phase 3Atea Pharmaceuticals, Inc.C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV | 2026-12 |
| NCT05390424University Hospital, RouenScreening for Hepatitis B, Hepatitis C and AIDS Viruses Using Dried Blood Spot | 2027-01 |
| NCT07038863Hospices Civils de LyonCommunity Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 174 studies in Hepatitis C with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main objective of this study is to analyse sexual behavior of HIV + MSM in Bordeaux, who have sexually contracted hepatitis C between January 1st 2013, to January 31, 2017. These data will bring some improvement about prevention and maybe reduced the hepatitis C incidence.
Hepatitis C (HCV) is considered in part as a sexually transmitted infection (STI). A marked decrease in its incidence has been observed for several years, coinciding with the availability of new direct acting antiviral treatments (DAA). However, people are increasingly infected with the hepatitis C virus, especially HIV-positive MSM. This increase is explained by new sexual practices that are particularly at high level of risk, despite the widening accessibility of new DAA. Prevention also plays an important role in implementing an effective risk reduction policy. New methods of prevention must therefore be developed. For this purpose, it is imperative to know the natural history of acute hepatitis C, the different behaviours at risk of HCV transmission, and the demonstration of socio-sexual networks (clusters) thanks to virological phylogenetic studies. In order to improve hepatitis C prevention, we wish to establish a descriptive study focusing on :
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
This study's enrollment of 29 is below the median of 218 across 435 observational studies indexed under Hepatitis C.
Browse Hepatitis C studies →University Hospital, Bordeaux is the lead sponsor of 807 studies on the registry; 198 are open to participants now.
Compared within Hepatitis C, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Acquired Immunodeficiency Syndrome. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Men who have sex with Men co-infected HIV-HCV
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: semi-directed interviews
semi-directed interviews in order to collect socio-behavioral data
Analyse sexual behaviours among HIV positive MSM in Bordeaux, through semi-directed interviews
Time frame: At inclusion (day 0)
Identifying socio-sexual networks through phylogenetic analysis
Time frame: At inclusion (day 0)
Describing the natural history of sexual hepatitis C in HIV positive MSM
Time frame: At inclusion (day 0)
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2017 to primary completion in Mar 2018, 4 months.
Of 102 non-industry observational studies under Hepatitis C, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 63. This study's 4 months is below that.
Counting every sponsor, half of 138 studies reached it within 33 months; a quarter within 18 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Bordeaux →